10-Q: Beauty Health Reports Q3 Loss Amid Sales Decline, Debt Restructuring

The Beauty Health Company reported a net loss of $11.0 million in Q3 2025, alongside a significant debt exchange and ongoing legal challenges.

Summary

• Net sales for the three months ended September 30, 2025, decreased by 10.3% to $70.7 million, compared to $78.8 million in the same period of 2024.
• Delivery Systems net sales declined by 24.6% to $20.8 million in Q3 2025, impacted by unfavorable macroeconomic and credit conditions across all regions.
• Consumables net sales slightly decreased by 2.6% to $49.8 million in Q3 2025, with declines related to the transition of the China market to a distributor partner.
• Gross profit increased by 12.3% to $45.6 million in Q3 2025, and gross margin improved significantly to 64.6% from 51.6% in Q3 2024, primarily due to lower inventory-related charges and a favorable mix shift towards consumables.
• Operating expenses decreased by 16.5% to $51.9 million in Q3 2025, driven by lower personnel-related expenses, including share-based compensation, and reduced depreciation and amortization.
• Net loss for Q3 2025 improved to $11.0 million, compared to a net loss of $18.3 million in Q3 2024.
• For the nine months ended September 30, 2025, net sales decreased by 12.9% to $218.4 million, while net loss significantly improved to $1.4 million from $18.8 million in the prior year period.
• The company completed a debt exchange on May 21, 2025, exchanging $413.2 million aggregate principal amount of 1.25% Convertible Senior Notes due 2026 (2026 Notes) for $250.0 million principal amount of new 7.95% Convertible Senior Secured Notes due 2028 (2028 Notes) and repurchasing $150.1 million principal amount of 2026 Notes for $142.6 million cash, resulting in a net gain of $16.6 million.
• Cash, cash equivalents, and restricted cash stood at $219.4 million as of September 30, 2025, a decrease from $370.1 million at December 31, 2024.
• The company is facing multiple ongoing legal proceedings, including a securities class action, a customer class action, a consolidated derivative action, and an SEC investigation, in addition to several patent and trademark infringement lawsuits.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to a material weakness in the inventory process, with remediation efforts ongoing and anticipated to be completed during fiscal year 2025.

Sentiment

Score: 3

Explanation: While the company improved its net loss and gross margin, the significant decline in net sales, especially in Delivery Systems, and the substantial decrease in cash reserves are concerning. The ongoing and unresolved legal issues, including an SEC investigation and class action lawsuits, coupled with an ineffective internal control environment, create considerable uncertainty and risk. The debt restructuring, while reducing the 2026 notes, introduced higher interest 2028 notes.

Positives

• Gross profit increased by 12.3% to $45.6 million in Q3 2025, and gross margin improved significantly to 64.6% from 51.6% in Q3 2024, driven by lower inventory charges and a favorable mix shift towards consumables.
• Net loss for Q3 2025 improved to $11.0 million from $18.3 million in Q3 2024, and for the nine months ended September 30, 2025, net loss significantly improved to $1.4 million from $18.8 million in the prior year period.
• Operating expenses decreased by 16.5% in Q3 2025 and 13.8% for the nine months, indicating effective cost management.
• The company successfully completed a debt exchange and repurchase of 2026 Notes, reducing the principal amount of older debt and extending maturity for a portion, resulting in a $16.6 million net gain.
• An initial determination in the ITC Cartessa Matter found Hydrafacial's patent valid and infringed, recommending an exclusion order and cease and desist order against Cartessa.
• Several patent and trademark infringement cases (Medical Purchasing Resource, Luvo, MS Essentials, eMIRAmed) have been settled or dismissed, reducing legal exposure.

Negatives

• Total net sales decreased by 10.3% in Q3 2025 and 12.9% for the nine months ended September 30, 2025, indicating a decline in core business revenue.
• Delivery Systems net sales, a key product line, saw a significant drop of 24.6% in Q3 and 35.7% for the nine months, attributed to unfavorable macroeconomic and credit conditions.
• Cash, cash equivalents, and restricted cash declined substantially by $150.7 million from December 31, 2024, to September 30, 2025, reflecting significant cash usage.
• Interest expense increased by 155.7% in Q3 2025 and 63.0% for the nine months, primarily due to the higher interest rate on the new 7.95% Convertible Senior Secured Notes due 2028.
• Interest income decreased by 74.2% in Q3 2025 and 48.4% for the nine months due to lower average invested balances and interest rates.
• Disclosure controls and procedures were not effective as of September 30, 2025, due to a material weakness in the inventory process, indicating internal control deficiencies.
• Ongoing legal proceedings, including a securities class action, customer class action, consolidated derivative action, and an SEC investigation, present considerable uncertainty and potential future liabilities.
• Mediation failed to reach a settlement in both the Securities Class Action and Customer Class Action, indicating prolonged litigation.
• The court denied the motion to dismiss in the Securities Class Action, meaning the case will proceed.

Risks

• Global economic conditions, including inflation, recession, changes in foreign currency exchange rates, and higher interest rates, may impact the business in unpredictable ways.
• The imposition of tariffs and/or trade restrictions may impact material costs and pricing.
• Disruptions in transportation and other supply chain related constraints, such as labor strife in the transportation industry.
• Issues related to older models of Syndeo devices and the company's actions to remediate such issues.
• Pricing actions taken to offset cost pressures could have an adverse impact on demand.
• Management's judgment in assessing legal matters may prove materially inaccurate, potentially leading to losses in excess of recorded amounts.
• The terms of the 2028 Notes contain restrictive covenants that may limit the company's ability to incur certain indebtedness, liens, investments, restricted payments, mergers, acquisitions, and dividends/repurchases of Class A Common Stock.
• Negative trends in financial performance or condition may result in a sustained decline in stock price, potentially triggering an interim goodwill impairment assessment and goodwill impairment.
• Inability to successfully identify suitable acquisition candidates, complete acquisitions, integrate acquired businesses, or expand into new markets.
• Inability to obtain additional financing on commercially reasonable terms if cash generated from operations is insufficient to satisfy capital requirements.

Future Outlook

The company expects to continue executing its plan to expand its global footprint by selling and placing hydradermabrasion delivery systems, driving consumables sales, investing in its community of providers, partners, and consumers, building brand awareness, and optimizing its global infrastructure. Remediation activities for the material weakness in internal control over financial reporting related to the inventory process are anticipated to be completed during fiscal year 2025. The company believes it has sufficient liquidity to satisfy anticipated working capital requirements for ongoing operations and obligations for at least the next 12 months, but will continue to evaluate capital expenditure needs based on factors such as revenue growth, potential acquisitions, R&D spending, and market acceptance.

Management Comments

• We believe we can be successful in our current operating environment.
• We remain attentive to business and macroeconomic conditions that may materially impact our business, and we continue to explore and implement reporting and quality management systems and risk mitigation strategies to remain agile in adapting to changing circumstances.
• Management believes that we have sufficient liquidity to satisfy our anticipated working capital requirements for our ongoing operations and obligations for at least the next 12 months.
• If cash flows from operations become insufficient to continue operations at the current level, and if no additional capital were obtained, then management would restructure the Company in a way to preserve our business while maintaining expenses within operating cash flows.

Industry Context

The company operates in the medtech and beauty industry, providing skin health experiences through brands like Hydrafacial, SkinStylus, and Keravive. Its customers are primarily in the medical (dermatologists, plastic surgeons), esthetician, and beauty retail industries. The filing notes that while no significant revenue reduction has been seen from industry consolidations to date, such events could adversely impact future revenues and earnings. Macroeconomic challenges, including inflation, recession, higher interest rates, tariffs, and supply chain disruptions, are impacting the global economy and the beauty health industry, potentially affecting providers' budgets and demand for products.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison to global benchmarks or industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Class Action**: Filed November 16, 2023, alleging misleading statements/omissions regarding Syndeo 1.0 and 2.0 devices. Motion to dismiss denied on September 25, 2025. Defendants' answer due November 24, 2025. Mediation on March 27, 2025, failed to settle.
• **Customer Class Action**: Filed October 24, 2024, alleging defective Syndeo machines and misrepresentations. Mediation on April 29, 2025, failed to settle. Amended complaint filed June 2, 2025, by multiple plaintiffs. Defendants moved to dismiss parts of it on June 23, 2025.
• **Consolidated Derivative Action**: Consolidated from two complaints (Elstein, Feb 8, 2024; Montague, May 1, 2024), alleging breach of fiduciary duty, gross mismanagement, waste, unjust enrichment, and aiding and abetting related to Syndeo devices. Mediation on November 4, 2025, reached agreement on certain terms, but settlement discussions are ongoing. Oral argument on motion to dismiss scheduled for January 7, 2026.
• **SEC Subpoena**: Received January 11, 2024, for a formal investigation related to the Securities Class Action allegations. The company is cooperating.
• **Cartessa Aesthetics, LLC (Patent Infringement)**: Hydrafacial filed complaint December 14, 2020. Federal Circuit Court of Appeals appeal filed October 8, 2024, challenging non-infringement ruling on one patent. Hearing expected in late 2026.
• **ITC Cartessa Matter (Patent Infringement)**: Hydrafacial filed complaint June 11, 2024, asserting infringement of U.S. Patent No. 11,865,287. Initial determination on August 26, 2025, found patent valid and infringed, recommending exclusion and cease and desist orders. Final determination expected by end of 2025.
• **Second Cartessa Case (Patent Infringement)**: Hydrafacial filed complaint June 14, 2024, asserting infringement of U.S. Patent No. 11,865,287. Stayed pending resolution of ITC Cartessa Matter.
• **Eunsung Global Corp (IPRs)**: Eunsung filed multiple IPRs challenging Hydrafacial patents (Sept 30, 2024; Jan 10, 2025; Jan 13, 2025; Jan 14, 2025). Eunsung terminated its IPR proceedings in July 2025.
• **Sinclair Pharma Ltd and Aesthetic Management Partners, Inc. (IPRs)**: Filed IPRs challenging Hydrafacial patents (Nov 25, 2024; July 2025). One IPR instituted June 2, 2025; others awaiting institution decisions in H1 2026.
• **Medicreations LLC (Patent Infringement)**: Hydrafacial filed complaint May 6, 2024, alleging infringement of twelve patents. Motion for Preliminary Injunction denied October 2025. Case proceeding through discovery.
• **Sinclair Pharma US, Inc (Patent Infringement)**: Hydrafacial filed complaint July 24, 2024, alleging infringement of five patents. Stay lifted, case proceeding into discovery.
• **Aesthetic Management Partners Inc. (Patent Infringement)**: Hydrafacial filed complaint July 8, 2024, alleging infringement of five patents. Stay lifted. Motion for preliminary injunction filed June 13, 2025, hearing held July 25, 2025, no order yet. Partial motion to dismiss filed June 23, 2025.
• **Medical Purchasing Resource, LLC (Trademark Infringement)**: Hydrafacial filed complaint June 4, 2024. Settled April 3, 2025, for $105,000 in damages and agreement to stop infringing activities. Case dismissed.
• **Luvo Medical Technologies Inc (Patent Infringement)**: Hydrafacial filed complaint August 16, 2024. Settled July 2025, case dismissed.
• **ITC Luvo Matter (Patent Infringement)**: Hydrafacial filed complaint August 7, 2024. Settled with Luvo and Healthcare Markets March 17, 2025. Default judgment against remaining respondents.
• **eMIRAmed USA, LLC (Patent Infringement)**: Hydrafacial filed complaint August 26, 2024. Default judgment granted against manufacturer MIRAmedtech, denied against eMIRAmed due to bankruptcy. Case closed.
• **Med Spa Essentials, LLC (Trademark Infringement)**: Hydrafacial filed complaint March 6, 2025. Settled July 2025, business shut down, case dismissed.
• **Candela Corp. (Patent Infringement)**: Hydrafacial filed complaint April 3, 2025, alleging infringement of five patents. Early stages of discovery.
• **BQ Aesthetix & Co., LLC (Patent Infringement)**: Hydrafacial filed complaint June 24, 2025, alleging infringement of seven patents. Early stages of discovery.

Related Party Transactions

• **Registration Rights Agreement**: Entered May 4, 2021, with BLS Investor Group LLC and Hydrafacial Stockholders, granting registration rights for Class A Common Stock.
• **Investor Rights Agreement**: Entered May 4, 2021, with LCP Edge Holdco, LLC, granting LCP rights to designate directors to the Board and representation on certain committees based on Class A Common Stock holdings.

Stakeholder Impact

• **Shareholders**: Impacted by declining sales, increased interest expense, ongoing legal uncertainties, and potential dilution if future capital raises involve equity. The material weakness in internal controls could also affect investor confidence.
• **Customers (Providers)**: Affected by issues related to Syndeo devices, as alleged in the Customer Class Action, potentially impacting their operations and trust in the company's products.
• **Employees**: Personnel-related expenses decreased, which could indicate workforce adjustments. Share-based compensation is a significant component of compensation.
• **Creditors (Noteholders)**: The debt exchange reduced the principal of 2026 Notes but introduced new 2028 Notes with a higher interest rate and secured status, impacting the company's debt profile and potentially the risk for unsecured creditors.
• **Suppliers**: Potential impact from supply chain disruptions and cost pressures mentioned in macroeconomic conditions.

Next Steps

• Defendants' answer to the amended complaint in the Securities Class Action is due November 24, 2025.
• The ITC Cartessa Matter is expected to issue a final determination by the end of 2025.
• Remediation activities for the material weakness in internal control over financial reporting are anticipated to be completed during fiscal year 2025.
• Oral argument before the Delaware Court of Chancery on the Motion to Dismiss in the Consolidated Derivative Action is scheduled for January 7, 2026.
• Settlement discussions are ongoing for the Consolidated Derivative Action, subject to execution of a final agreement and court approval.
• Institution decisions for the remaining Sinclair and AMP IPRs are expected in the first half of 2026.
• The hearing for the Cartessa Case appeal is expected to be scheduled in the later half of 2026.
• The company will continue to evaluate its capital expenditure needs.

Key Dates

Recommendation

While the company showed an improvement in net loss and gross margin, the significant decline in net sales, particularly in Delivery Systems, is a major concern. The substantial cash burn and increased interest expense from the debt restructuring add financial pressure. The multitude of ongoing legal proceedings, including class actions and an SEC investigation, create significant uncertainty and potential liabilities. The identified material weakness in internal controls further complicates the outlook. The positive resolution of some patent disputes and the ITC ruling are favorable, but not enough to outweigh the broader operational and legal challenges. A 'hold' recommendation is appropriate given the mixed results and high level of uncertainty, suggesting investors monitor the resolution of legal issues and sales trends closely before making further investment decisions.

Keywords

Beauty Health Company, Hydrafacial, Medtech, Skin health, Quarterly report, Financial results, SEC filing, Convertible notes, Debt exchange, Legal proceedings, Class action, Patent infringement, SEC investigation, Syndeo, Consumables, Delivery systems, Gross margin, Net loss, Operating expenses, Corporate governance, Internal controls, Risk factors